Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H27ClN2O8.H2O |
| Molecular Weight | 536.959 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChIKey=KXDLNFYVIGTHGT-HQKSCHDUSA-N
InChI=1S/C25H27ClN2O8.H2O/c1-13-17(10-22(32)27-19(11-29)23(33)24(34)21(31)12-30)18-9-16(36-2)7-8-20(18)28(13)25(35)14-3-5-15(26)6-4-14;/h3-9,11,19,21,23-24,30-31,33-34H,10,12H2,1-2H3,(H,27,32);1H2/t19-,21+,23+,24+;/m0./s1
Glucametacin is a non-steroidal anti-inflammatory, analgesic, antipyretic agent. Glucametacin was compared with ketoprofen in a double-blind, crossover trial. The drugs were given in total daily doses of 420 mg glucametacin and 300 mg ketoprofen for 20 days to 30 patients with chronic arthropathies of an inflammatory or degenerative nature. Both drugs were well tolerated and resulted in significant improvements in a number of criteria of disease assessment. Although there were no significant differences between results seen with the two drugs, there appeared to be trends in favour of glucametacin in respect to both efficacy and tolerance.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m5753
Created by
admin on Mon Mar 31 21:58:59 GMT 2025 , Edited by admin on Mon Mar 31 21:58:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
8923CH1NY1
Created by
admin on Mon Mar 31 21:58:59 GMT 2025 , Edited by admin on Mon Mar 31 21:58:59 GMT 2025
|
PRIMARY | |||
|
21150895
Created by
admin on Mon Mar 31 21:58:59 GMT 2025 , Edited by admin on Mon Mar 31 21:58:59 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
